Regeneron Pharmaceuticals holds the cleaner structural position, with the lead spread across valuation and profitability. Danaher still has the edge on growth, which keeps the comparison from looking entirely one-sided. On the market side, Regeneron Pharmaceuticals is in better shape — its trend is intact while Danaher's trend has broken down. That puts structure and market broadly in agreement — Regeneron Pharmaceuticals's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
The lead is spread across valuation and profitability, rather than sitting in one isolated gap. Regeneron Pharmaceuticals, Inc. leads by 14 points on the overall comparison score.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
This level of similarity points to a meaningful structural match, though not a tight one.
The strongest overlap appears in recent revenue growth and margin trend.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Structure stays fairly close here, while current pricing still looks more supportive for Regeneron Pharmaceuticals, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where DHR and REGN each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 8.4 turns lower.
Earnings growth also leans toward DHR, which keeps the score lead from reading as a full growth sweep.
The lead is built on both valuation and profitability — though growth still provides a counterweight.
Break down the DHR vs REGN comparison across all dimensions with the full interactive tool.
Explore how DHR and REGN each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.